annb0t
Top 20
Mesoblast Limited
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023.
Mesoblast Chief Executive Silviu Itescu said: âDuring the period we had a very productive meeting with the United States Food and Drug Administration (FDA), which has allowed us to establish the path forward for potential pediatric a...
>>> Read more: Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023.
Mesoblast Chief Executive Silviu Itescu said: âDuring the period we had a very productive meeting with the United States Food and Drug Administration (FDA), which has allowed us to establish the path forward for potential pediatric a...
>>> Read more: Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
